Physician profile
Benjamin Aziz Talei
NPI 1144472879
$30,580.27
in general payments reported to CMS, 2019-2025
14 companies · $8,718 in 2025
The $8,718 reported for 2025 was more than what 97% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $5,320 · 2021: $4,355 · 2022: $504 · 2023: $510 · 2024: $679 · 2025: $8,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $8,000 · Food and Beverage: $1,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $8,000.00 |
| Food and Beverage | $1,907.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $19,414.63 | 2019-2025 | Dysport |
| Abbvie INC. | $9,203.86 | 2022-2025 | Botox |
| Allergan, INC. | $556.32 | 2019-2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $296.14 | 2024-2025 | Fraxel, Clear & Brilliant |
| Sientra, INC. | $253.75 | 2020-2021 | |
| Tepha INC | $236.97 | 2020 | |
| Revance Therapeutics, INC. | $133.33 | 2025 | Daxxify |
| Amgen INC. | $121.07 | 2019 | |
| Axogen | $113.37 | 2022 | |
| Stryker Corporation | $84.03 | 2019 | |
| Becton, Dickinson and Company | $76.92 | 2025 | Arista |
| Bard Peripheral Vascular, INC. | $49.74 | 2021 | |
| Tela Bio, INC. | $20.97 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Solventum Corporation | $19.17 | 2024 | Snap, Promogran Prisma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Talei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.